

## **Thai Plaspac**

TPAC TB / TPACm.BK

May 14, 2021

# Good 1Q21 core profit as expected, but extra expenses hit bottom-line

## Core profit in line; bottom-line miss

TPAC reported a 1Q21 net loss of Bt20m, a reversal from the net profits posted for 1Q20 and 4Q20. Stripping out Bt133m in non-recurring tax expenses (tied to amended tax rules related to goodwill in India) and a Bt2m gain on FX, core earnings would be Bt112m, up by 32% YoY and 77% QoQ. While the core profit was in line with our estimate, we had expected the bottom-line to be written in black ink, not red.

## Result highlights

The core earnings growth drivers were: 1) a QoQ operational improvement in the Thailand business and 2) a YoY and QoQ better profit at SUNPET (the operating business in India and the UAE). The core EBITDA of the Thailand business was Bt75m, down 26% YoY (a slimmer GM, squeezed by steeply higher feedstock costs) but up 84% QoQ (a fatter GM). The core EBITDA of SUNPET stood at Bt175m, up by 30% YoY and 19% QoQ, driven by greater sales volume and a fatter GM.

## **Outlook**

TPAC's 2Q21 core earnings look set to expand further YoY, buoyed by greater sales volume (stronger demand for packaging across all client types—food & beverage, pharmaceutical & personal care, and home care & industrial) and fatter margin. Core earnings should also rise QoQ, driven by contributions by an asset acquired during the quarter (Combi-Pack, a manufacturer of innovative rigid plastic food packaging in Malaysia; the deal is expected to be sealed by May 31, 2021).

## What's changed?

1Q21 core profit represents 25% of our 2021 core earnings forecast of Bt443m, which we maintain unchanged. But we have slashed our net profit projection by 30% to Bt310m to reflect extra expenses booked to the 1Q21 income statement. Our YE21 DCF-derived target price is trimmed to Bt17.90 from Bt18.

## Recommendation

Expectations of YoY core earnings growth for 2Q21 and 2021, driven by structurally expanding demand for consumer-linked packaging and acquisitions, should catalyze the share price going forward. Moreover, we expect TPAC to deliver superior EBITDA and earnings growth, as well as margin expansion, through 2023. But the market hasn't yet anticipated or priced that in, we believe.

The stock currently trades at low valuation metrics compared with its peers—a 2021 PER of 16.0x (a 37% discount to the peer mean of 25.6x) and a YE21 PBV of 2.1x (47% below the average peer PBV of 4.0x). TPAC currently trades on the MAI (not the SET), which entails some discount to being SET-listed, but its strong earnings growth profile and scope for upside should eventually narrow the discount gap. Any share price dip resulting from its disappointing 1Q21 bottom-line would open an opportunity to BUY!

## Sector: MAI/Industrial

Rating: BUY Target Price: Bt17.90 Price (May 13, 2021): Bt15.20

## **Key statistics**

ney statistics						
Market cap		Bt5.0bn	USD0.2bn			
12-mth price range	Bt9.5	5/Bt17.2				
12-mth avg daily volume	Bt6m USD0.2m					
# of shares (m)	327					
Est. free float (%)	20.4					
Foreign limit (%)		49.0				
Share price perf. (%)	1M	3M	12M			
Relative to SET	33.4	18.0	29.4			
Absolute	33.3	19.7	49.0			

#### **Financial summary**

	-			
FY Ended 31 Dec	2020	2021E	2022E	2023E
Revenues (Btm)	3,983	5,565	6,429	6,824
Net profit (Btm)	322	310	495	540
EPS (Bt)	0.99	0.95	1.52	1.65
EPS growth (%)	+131.9%	-3.7%	+59.7%	+9.0%
Core profit (Btm)	316	443	495	540
Core EPS (Bt)	0.97	1.36	1.52	1.65
Core EPS growth (%)	+87.4%	+40.4%	+11.7%	+9.0%
PER (x)	11.2	16.0	10.0	9.2
PBV (x)	1.7	2.1	1.8	1.6
Dividend (Bt)	0.3	0.3	0.5	0.5
Dividend yield (%)	2.6	1.9	3.0	3.3
ROE (%)	16.9	14.3	20.0	18.8

**CG/Anti-corruption** 




Suppata Srisuk Securities Fundamental Investment Analyst suppata@bualuang.co.th +66 2 618 1343

See disclaimer at the end of report



## **TPAC: Financial Tables - Year**


PROFIT & LOSS (Btm)	2019	2020	2021E	2022E	2023E
Revenue	3,756	3,983	5,565	6,429	6,824
Cost of sales and services	(3,096)	(3,025)	(4,211)	(4,855)	(5,149)
Gross profit	660	957	1,354	1,573	1,676
SG&A	(410) <b>249</b>	(473) <b>485</b>	(658) <b>696</b>	(757) <b>817</b>	(803)
EBIT	(141)	(105)	(134)	(187)	<b>872</b> (187)
Interest expense Other income/exp.	42	51	56	61	67
EBT	150	430	618	691	753
Corporate tax	9	(83)	(119)	(133)	(145)
After-tax net profit (loss)	159	347	499	558	608
Minority interest	(24)	(31)	(56)	(63)	(68)
Equity earnings from affiliates Extra items	0 4	0 6	0 (133)	0 0	0
Net profit (loss)	139	322	310	495	540
Reported EPS	0.53	0.99	0.95	1.52	1.65
Fully diluted EPS	0.43	0.99	0.95	1.52	1.65
Core net profit	134	316	443	495	540
Core EPS	0.52 <b>580</b>	0.97 <b>856</b>	1.36	1.52 <b>1,263</b>	1.65 <b>1,370</b>
EBITDA	300	030	1,088	1,203	1,370
KEY RATIOS Revenue growth (%)	48.6	6.0	39.7	15.5	6.2
Gross margin (%)	17.6	24.0	24.3	24.5	24.6
EBITDA margin (%)	15.4	21.5	19.5	19.6	20.1
Operating margin (%)	6.6	12.2	12.5	12.7	12.8
Net margin (%)	3.7	8.1	5.6	7.7	7.9
Core profit margin (%)	3.6	7.9	8.0	7.7	7.9
ROA (%) ROCE (%)	3.2 4.1	7.1 8.4	5.1 5.7	6.3 7.1	6.5 7.3
Asset turnover (x)	0.9	0.9	0.9	0.8	0.8
Current ratio (x)	1.5	1.3	0.0	0.0	0.0
Gearing ratio (x)	0.9	1.0	1.9	1.7	1.4
Interest coverage (x)	1.8	4.6	5.2	4.4	4.7
BALANCE SHEET (Btm)					
Cash & Equivalent	35	196	150	151	137
Accounts receivable Inventory	784 287	826 416	1,154 581	1,333 671	1,415 712
PP&E-net	1,481	1,476	3,061	3,170	3,064
Other assets	1,619	1,686	2,356	2,722	2,889
Total assets	4,387	4,723	7,474	8,246	8,429
Accounts payable	293	359	502	579	615
ST debts & current portion Long-term debt	566 1,076	764 1,264	1,087 3,246	1,299 3,279	1,155 3,157
Other liabilities	578	166	233	269	285
Total liabilities	2,537	2,603	5,138	5,508	5,299
Paid-up capital	327	327	327	327	327
Share premium	1,027	1,027	1,027	1,027	1,027
Retained earnings	665 <b>1,744</b>	945 <b>2,062</b>	1,160 <b>2,276</b>	1,562 <b>2,678</b>	1,953 <b>3,070</b>
Shareholders equity Minority interests	105	<b>2,002</b> 59	60	60	61
Total Liab.&Shareholders' equity	4,387	4,723	7,474	8,246	8,429
CASH FLOW (Btm)					
Net income	163	353	310	495	540
Depreciation and amortization	289	321	336	385	430
Change in working capital	(18)	(96)	(983)	(537)	(246)
FX, non-cash adjustment & others  Cash flows from operating activities	104 <b>537</b>	184 <b>762</b>	(338)	<b>343</b>	<b>724</b>
Capex (Invest)/Divest	(216)	(309)	(1,921)	(494)	(324)
Others	(415)	67	Ó	` ó	Ò
Cash flows from investing activities	(631)	(242)	(1,921)	(494)	(324)
Debt financing (repayment)	(678)	283	2,306	244	(266)
Equity financing Dividend payment	797 0	0 (41)	0 (95)	0 (93)	0 (149)
Others	(415)	67	(95)	(93)	(149)
Cash flows from financing activities	119	242	2,212	152	(414)
Net change in cash	25	762	(46)	1	(14)
Free cash flow (Btm)	322	453	(2,258)	(151)	400
Key assumptions	2019	2020	2021E	2022E	2023E
Sales volume (kt)	na	53,484	63,881	72,465	80,280
Overall utilization rate	na	70%	77%	80%	82%





**TPAC: Financial Tables - Quarter** 

QUARTERLY PROFIT & LOSS (Btm)	1Q20	2Q20	3Q20	4Q20	1Q21
Revenue	1,039	926	1,036	982	1,089
Cost of sales and services	(787)	(696)	(791)	(752)	(815)
Gross profit	252	230	246	230	274
SG&A	(117)	(105)	(121)	(130)	(120)
EBIT	135	125	125	99	154
Interest expense	(29)	(25)	(25)	(26)	(26)
Other income/exp.	` <u>8</u>	14	14	15	13
EBT	114	113	114	88	141
Corporate tax	(21)	(17)	(23)	(22)	(25)
After-tax net profit (loss)	`94	`96	92	`66	116
Minority interest	(9)	(7)	(12)	(3)	(4)
Equity earnings from affiliates	Ó	`ó	` ó	Ó	`ó
Extra items	7	(1)	0	0	(132)
Net profit (loss)	91	88	80	63	(20)
Reported EPS	0.28	0.27	0.24	0.19	(0.06)
Fully diluted EPS	0.28	0.27	0.24	0.19	(0.06)
Core net profit	84	89	80	63	112
Core EPS	0.26	0.27	0.24	0.19	0.34
EBITDA	220	204	207	175	237
KEY RATIOS					
Gross margin (%)	24.3	24.8	23.7	23.4	25.1
EBITDA margin (%)	21.2	22.0	19.9	17.8	21.8
Operating margin (%)	13.0	13.5	12.1	10.1	14.1
Net margin (%)	8.8	9.5	7.7	6.5	(1.8)
Core profit margin (%)	8.1	9.6	7.7	6.4	10.2
BV (Bt)	6.3	6.1	6.7	6.5	6.8
ROE (%)	19.6	18.3	16.2	12.3	(3.8)
ROA (%)	7.9	7.4	6.7	5.3	(1.7)
Current ratio (x)	1.4	1.4	1.0	1.3	1.4
Gearing ratio (x)	0.9	0.9	0.7	1.0	0.9
Interest coverage (x)	4.7	4.9	5.0	3.8	5.9
QUARTERLY BALANCE SHEET (Btm)					
Cash & Equivalent	183	361	271	196	243
Accounts receivable	864	764	804	826	911
Inventory	329	290	316	416	517
PP&E-net	1,560	1,514	1,549	1,476	1,542
Other assets	1,802	1,720	1,771	1,686	1,736
Total assets	4,782	4,688	4,774	4,723	5,020
Accounts payable	283	338	322	359	344
ST debts & current portion	655	647	625	764	877
Long-term debt	1,118	1,054	956	1,264	1,191
Other liabilities	634	622	155	166	328
Total liabilities	2,735	2,709	2,591	2,603	2,799
Paid-up capital	327	327	327	327	327
Share premium	1,027	1,027	1,027	1,027	1,027
Retained earnings	756	803	883	945	926
Shareholders equity	1,968	1,877	2,062	2,062	2,155
Minority interests	79	102	121	59	66
Total Liab.&Shareholders' equity	4,782	4,688	4,774	4,724	5,020
. J.a. L.a.J. aonai onoidoro oquity	-,	.,	-,	-,	-,3



## Company profile

Thai Plaspac Plc (TPAC) designs and manufactures rigid plastic packaging for clients in the food & beverage, FMCG, pharmaceutical, personal hygiene, and homecare industries. TPAC's packaging solutions use a selected range of plastic polymers that are all recyclable and/or made from recycled materials. It has a total of 10 production facilities in four countries—Thailand (4), India (5), and the United Arab Emirates (1).



Figure 1: 1Q21 results

FY Ended 31 Dec (Btm)	1Q21	1Q20	YoY %	4Q20	QoQ %	3M21	3M20	YoY %	3M21 vs. FY21E	
Income Statement										
Revenue	1,089	1,039	5	982	11	1,089	1,039	5	20	
Cost of sales and services	(815)	(787)	4	(752)	8	(815)	(787)	4	19	<ul> <li>The YoY revenue growth was</li> </ul>
EBITDA	237	220	8	175	36	237	220	8	22	· ·
SG&A	(120)	(117)	2	(130)	(8)	(120)	(117)	2	18	driven by higher sales at SUNPET
EBIT	154	135	14	99	55	154	135	14	22	
Interest expense	(26)	(29)	(10)	(26)	(1)	(26)	(29)	(10)	19	The OoO ten line expension was
Other income/exp.	13	8	60	15	(12)	13	8	60	23	<ul> <li>The QoQ top-line expansion was</li> </ul>
Equity earnings from affiliates	0	0	0	0	0	0	0	0	n.m.	boosted by greater sales in
Extra items	(132)	7	nm	0	nm	(132)	7	nm	99	Thailand and at SUNPET
EBT	141	114	23	88	60	141	114	23	23	manara ana at com Er
Corporate tax	(25)	(21)	22	(22)	13	(25)	(21)	22	21	
Minority interest	(4)	(9)	(56)	(3)	54	(4)	(9)	(56)	7	<ul> <li>GM expanded YoY and QoQ</li> </ul>
Net profit (loss)	(20)	91	nm	63	nm	(20)	91	nm	(7)	*On expanded for and ded
Reported EPS	(0.06)	0.28	nm	0.19	nm	(0.06)	0.28	nm	(7)	
Core net profit	112	84	32	63	77	112	84	32	25	<ul> <li>Gain on FX</li> </ul>
Key ratios										
Gross margin (%)	25.1	24.3		23.4		25.1	24.3			<ul> <li>Non-recurring tax expenses</li> </ul>
EBITDA margin (%)	21.8	21.2		17.8		21.8	21.2			enon-recurring tax expenses
EBIT margin (%)	14.1	13.0		10.1		14.1	13.0			
SG&A / Revenue (%)	11.0	11.3		13.2		11.0	11.3			<ul> <li>The bottom-line was weaker than</li> </ul>
Tax rate (%)	17.9	18.1		25.4		17.9	18.1			
Net margin (%)	(1.8)	8.8		6.5		(1.8)	8.8			we had modeled—a loss; we had
Interest coverage (x)	5.9	4.7		3.8		5.9	4.7			expected black ink
Balance Sheet										
Cash & Equivalent	243	183	33	196	24					<ul> <li>The core profit was in line with our</li> </ul>
Total assets	5,020	4,782	5	4,723	6					
ST debts & current portion	877	655	34	764	15					projection
Long-term debt	1,191	1,118	7	1,264	(6)					
Total liabilities	2,799	2,735	2	2,603	8					
Retained earnings	926	756	23	945	(2)					
Shareholders equity	2,155	1,968	10	2,062	5					
Minority interests	66	79	(17)	59	12					
	00	, ,	( ' ' ' )	00	12					

Source: Bualuang Research estimates



## **Bualuang Securities Public Company Limited**

## **DISCLAIMER**

BUALUANG SECURITIES PUBLIC COMPANY LIMITED (BLS) is a subsidiary of BANGKOK BANK PUBLIC COMPANY LIMITED (BBL). This document is produced based upon sources believed to be reliable but their accuracy, completeness or correctness is not guaranteed. The statements or expressions of opinion herein were arrived at after due and careful consideration to use as information for investment. Expressions of opinion contained herein are subject to change without notice. This document is not, and should not be construed as, an offer or the solicitation of an offer to buy or sell any securities. The use of any information shall be at the sole discretion and risk of the user.

BUALUANG SECURITIES PUBLIC COMPANY LIMITED MAY BE IN RELATIONSHIP WITH THE SECURITIES IN THIS REPORT. "Opinions, projections and other information contained in this report are based upon sources believed to be accurate including the draft prospectus, but no responsibility is accepted for any loss occasioned by reliance placed upon the contents hereof. Bualuang Securities Public Company Limited may from time to time perform investment, advisory or other services for companies mentioned in this report, as well as dealing (as principal or otherwise) in, or otherwise being interested in, any securities mentioned herein, This report does not constitute a solicitation to buy or sell any securities". Investors should carefully read details in the prospectus before making investment decision.

BUALUANG SECURITIES PUBLIC COMPANY LIMITED MAY ACT AS MARKET MAKER AND ISSUER OF DWs, AND ISSUER OF STRUCTURED NOTES ON THESE SECURITIES. The company may prepare the research reports on those underlying securities. Investors should carefully read the details of the derivative warrants and structured notes in the prospectus before making investment decisions.

ADVANC	AEONTS	AMATA	AOT	BDMS	BH	BJC	CBG	CENTEL	CPALL	DTAC	EGCO	GLOBAL	GPSC	IRPC
KBANK	KCE	KTC	MINT	PTG	PIT	PITEP	PTTGC	SCB	SPRC	TASCO	TKN	TOP	WHA	ESSO
CKP	STA	BGRIM	GULF	MTC	AWC	TCAP	CRC	CPF	CPN	HANA	HMPRO	ⅣL	OSP	SAWAD
THANI	BANPU	BCH	BTS	CK	SCC	STEC	TISCO	TRUE	TU	INTUCH	RATCH	VGI	PRM	SCGP
TQM	COM7	DOHOME	JMT	CHG	TMB	BAM	BCP	BCPG	AP	KTB	BPP	KKP	OR	BEM
GUNKUL	LH	EA	QH	SPALI	RBF									

BUALUANG SECURITIES PUBLIC COMPANY LIMITED IS OR MAY BE AN UNDERWRITER/CO-UNDERWRITER/JOINT LEAD IN RESPECT OF THE INITIAL PUBLIC OFFERING (IPO) OF SECURITIES.

Financial Advisor	Lead underwriter/ Underwriter/ Co-underwriter
	OR, DITTO

## **CG** Rating

Score Range	Score Range	Description
90 – 100		Excellent
80 – 89		Very Good
70 – 79		Good
60 – 69	Delineral Delineral	Satisfactory
50 – 59	NAME OF THE PROPERTY OF THE PR	Pass
Below 50	No logo given	N/A

Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors

- companies that have **declared** their intention to join CAC, and
- · companies certified by CAC.



## CORPORATE GOVERNANCE REPORT DISCLAIMER

#### **Corporate Governance Report disclaimer**

The disclosure of the survey result of the Thai Institute of Directors Association (IOD) regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The IOD survey is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. Bualuang Securities Public Company Limited neither confirms nor certifies the accuracy of such survey results.

"Disclaimer: The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by the relevant institution as disclosed by the Office of the Securities and Exchange Commission, is made in order to comply with the policy and sustainable development plan for the listed companies. The relevant institution made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, Bualuang Securities Public Company Limited neither confirms, verifies, nor certifies the accuracy and completeness of the assessment result."

### BUALUANG RESEARCH - RECOMMENDATION FRAMEWORK

### STOCK RECOMMENDATIONS

**BUY:** Expected positive total returns of 15% or more over the next 12 months

**HOLD:** Expected total returns of between -15% and +15% over the next 12 months.

**SELL:** Expected negative total returns of 15% or more over the next 12 months.

**TRADING BUY:** Expected positive total returns of 15% or more over the next 3 months.

### **SECTOR RECOMMENDATIONS**

**OVERWEIGHT:** The industry, as defined by the analyst's coverage universe, is expected to outperform the relevant primary market index over the next 12 months. **NEUTRAL:** The industry, as defined by the analyst's coverage universe, is expected to perform in line with the relevant primary market index over the next 12 months.

**UNDERWEIGHT:** The industry, as defined by the analyst's coverage universe, is expected to underperform the relevant primary market index over the next 12 months.



### **IMPORTANT DISCLOSURES FOR U.S. PERSONS**

This research report was prepared by Bualuang Securities Public Company Limited ("BLS"). BLS is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through BLS. Rosenblatt Securities Inc. accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Rosenblatt Securities Inc. and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

### **Additional Disclosures**

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither BLS nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

BLS may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of BLS.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by BLS with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of BLS and BLS accepts no liability whatsoever for the actions of third parties in this respect.